ALLMedicine™ Anaplastic Large Cell Lymphoma Center

May 6th, 2021 - An effusion-based presentation of ALK- anaplastic large cell lymphoma.|2021|Zhao Y,Wang E,|

May 5th, 2021 - CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. We treated a pati...

May 4th, 2021 - CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing...

May 3rd, 2021 - Commentary on: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Are You Covered?|2021|Reisman NR,|

Apr 28th, 2021 - Primary central nervous system (CNS) mature T- and NK-cell lymphomas are rare, only comprising 2% to 3% of all primary CNS lymphomas. Among them, peripheral T-cell lymphoma, not otherwise specified, anaplastic large cell lymphoma (ALCL), and extra...

Feb 11th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

Feb 5th, 2019 - The Food and Drug Administration (FDA) wants to increase awareness about an association between all breast implants, regardless of filling or texture, and Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL). The FDA received repor...

Jan 30th, 2019 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that ari...

Jan 30th, 2019 - National Comprehensive Cancer Network (NCCN) guidelines represent the consensus standard of care for diagnosis and management of the majority of known cancers. NCCN guidelines on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) ...

Feb 11th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

May 6th, 2021 - An effusion-based presentation of ALK- anaplastic large cell lymphoma.|2021|Zhao Y,Wang E,|

May 5th, 2021 - CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. We treated a pati...

May 4th, 2021 - CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing...

May 3rd, 2021 - Commentary on: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Are You Covered?|2021|Reisman NR,|

Apr 28th, 2021 - Primary central nervous system (CNS) mature T- and NK-cell lymphomas are rare, only comprising 2% to 3% of all primary CNS lymphomas. Among them, peripheral T-cell lymphoma, not otherwise specified, anaplastic large cell lymphoma (ALCL), and extra...

Jul 9th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 9th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 8th, 2020 - As of April 2020, there have been 68 cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) reported in the UK. This figure includes cases where the original implantation did not occur in the UK. Based on the number of cases,...

The information in this letter has been superseded by The FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from the Market: FDA Sa...

Aug 21st, 2019 - Health professionals have been reminded to continue to report suspected cases of breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) in patients who have had breast implants or who have had them removed. In an update to two previou...